Immune checkpoints are essential components of the immune system designed to prevent overly aggressive immune responses that could harm healthy cells. These checkpoints are regulated by proteins on the surface of T cells, which can bind to partner proteins on other cells, including some cancer cells. When these proteins bind, they send an “off” signal to the T cells, effectively dampening the immune response and allowing cancer cells to evade destruction.
Immune checkpoint inhibitors are immunotherapy drugs that block these interactions, preventing the “off” signal from being sent. By doing so, these inhibitors enable T cells to remain active and attack cancer cells effectively.
For example: CTLA-4 inhibitors block the CTLA-4 protein, an immune checkpoint on T cells.
PD-1 inhibitors target the PD-1 protein on T cells, preventing it from binding to its partner, PD-L1, which is often produced in high amounts by tumor cells to suppress immune responses.
Cancers Treated with Immune Checkpoint Inhibitors
Immune checkpoint inhibitors have been approved for treating various cancers, including:
Breast cancer
Bladder cancer
Cervical cancer
Colon and rectal cancers
Head and neck cancers
Hodgkin lymphoma
Liver cancer
Lung cancer
Renal cell carcinoma (kidney cancer)
Skin cancers, including melanoma
Stomach cancer
Solid tumors with DNA repair deficiencies
The effectiveness of these drugs depends on the specific cancer type and individual patient characteristics.
Side Effects of Immune Checkpoint Inhibitors
Like all treatments, immune checkpoint inhibitors can cause side effects, which vary based on factors such as the patient’s health, cancer type, and the specific drug and dosage used.
Common Side Effects
Rash
Diarrhea
Fatigue
Rare and Severe Side Effects
In some cases, these drugs may cause widespread inflammation, leading to complications in various organs. Examples include:
Skin: Rash, changes in color, and itchiness caused by skin inflammation.
Lungs: Inflammation (pneumonitis) causing cough and chest pain.
Colon: Belly pain and diarrhea due to colitis.
Pancreas: Inflammation resulting in diabetes.
Liver: Hepatitis (inflammation of the liver).
Heart: Myocarditis (inflammation of the heart muscle).
Kidneys: Nephritis, leading to impaired kidney function.
Thyroid: Overactive or underactive thyroid.
Nervous System: Muscle weakness, numbness, or difficulty breathing due to nerve damage.
Managing Side Effects
Doctors closely monitor patients during treatment to identify and address side effects early. Patients should report any unusual symptoms promptly, as timely intervention can often prevent complications.
Conclusion
Immune checkpoint inhibitors, targeting pathways such as PD-1/PD-L1 and CTLA-4, have transformed cancer treatment by enhancing the activity of tumor- and host-specific cytotoxic T cells. However, their potent effects also lead to unique toxicities, and many patients seen in clinical practice, including those excluded or underrepresented in trials, face uncertainties about the safety and efficacy of these therapies.
They represent a breakthrough in cancer treatment by reactivating the immune system’s ability to fight cancer. While highly effective for many, they come with potential side effects that require careful management. Ongoing research aims to expand their use and improve safety, offering hope to patients with various types of cancer.
Read our article about Immunotherapy: How It Works and Its Role in Cancer Treatment
